Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis.
BRAF V600E
Low-grade glioma
Senescence
Surgery
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
18
07
2022
accepted:
18
10
2022
pubmed:
3
11
2022
medline:
21
12
2022
entrez:
2
11
2022
Statut:
ppublish
Résumé
Despite excellent long-term overall survival rates, pediatric low-grade gliomas (pLGG) show high variety of clinical behavior regarding progress or senescence post incomplete resection (IR). This study retrospectively analyzes tumor growth velocity (TGV) of pLGG before surgery and after IR to investigate the impact of surgical extent, tumor location and molecular BRAF status on postoperative residual tumor growth behavior. Of a total of 172 patients with pLGG receiving surgical treatment, 107 underwent IR (66%). Fifty-three vs 94 patients could be included in the pre- and post-operative cohort, respectively, and were observed over a mean follow-up time of 40.2 vs 60.1 months. Sequential three-dimensional MRI-based tumor volumetry of a total of 407 MRI scans was performed to calculate pre- and postoperative TGV. Mean preoperative TGV of 0.264 cm This data suggests that extensive surgical resection may impact pediatric LGG growth kinetics post incomplete resection by inducing a significant deceleration of tumor growth. BRAF-V600E mutation may be a risk factor for higher postoperative TGV.
Identifiants
pubmed: 36319795
doi: 10.1007/s11060-022-04176-4
pii: 10.1007/s11060-022-04176-4
pmc: PMC9758245
doi:
Substances chimiques
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
BRAF protein, human
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-576Informations de copyright
© 2022. The Author(s).
Références
Rickert CH, Paulus W (2001) Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst 17(9):503–511. https://doi.org/10.1007/s003810100496
doi: 10.1007/s003810100496
Bandopadhayay P, Bergthold G, London WB et al (2014) Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer 61(7):1173–1179. https://doi.org/10.1002/pbc.24958
doi: 10.1002/pbc.24958
Sievert AJ, Fisher MJ (2009) Pediatric low-grade gliomas. J Child Neurol 24(11):1397–1408. https://doi.org/10.1177/0883073809342005
doi: 10.1177/0883073809342005
Armstrong GT, Liu Q, Yasui Y et al (2009) Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 101(13):946–958. https://doi.org/10.1093/jnci/djp148
doi: 10.1093/jnci/djp148
Stokland T, Liu JF, Ironside JW et al (2010) A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). NeuroOncology 12(12):1257–1268. https://doi.org/10.1093/neuonc/noq092
doi: 10.1093/neuonc/noq092
Gnekow AK, Falkenstein F, von Hornstein S et al (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. NeuroOncology 14(10):1265–1284. https://doi.org/10.1093/neuonc/nos202
doi: 10.1093/neuonc/nos202
Wisoff JH, Sanford RA, Heier LA et al (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s Oncology Group. Neurosurgery 68(6):1548–1555. https://doi.org/10.1227/NEU.0b013e318214a66e
doi: 10.1227/NEU.0b013e318214a66e
Collins KL, Pollack IF (2020) Pediatric low-grade gliomas. Cancers (Basel) 12(5):1152. https://doi.org/10.3390/cancers12051152
doi: 10.3390/cancers12051152
Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L (2001) Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys 51(3):704–710. https://doi.org/10.1016/s0360-3016(01)01705-9
doi: 10.1016/s0360-3016(01)01705-9
Shaw EG, Wisoff JH (2003) Prospective clinical trials of intracranial low-grade glioma in adults and children. NeuroOncology 5(3):153–160. https://doi.org/10.1215/S1152851702000601
doi: 10.1215/S1152851702000601
Rozen WM, Joseph S, Lo PA (2008) Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr Neurosurg 44(4):324–328. https://doi.org/10.1159/000134925
doi: 10.1159/000134925
Schmandt SM, Packer RJ, Vezina LG, Jane J (2000) Spontaneous regression of low-grade astrocytomas in childhood. Pediatr Neurosurg 32(3):132–136. https://doi.org/10.1159/000028917
doi: 10.1159/000028917
Broniscer A, Baker SJ, West AN et al (2007) Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 25:682–689. https://doi.org/10.1200/JCO.2006.06.8213
doi: 10.1200/JCO.2006.06.8213
Avinash KS, Thakar S, Aryan S, Ghosal N, Hegde AS (2019) Malignant transformation of pediatric low-grade gliomas: report of two cases and review of a rare pathological phenomenon. Neurol India 67(4):1100–1106. https://doi.org/10.4103/0028-3886.266259
doi: 10.4103/0028-3886.266259
Ryall S, Zapotocky M, Fukuoka K et al (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37(4):569-583.e5. https://doi.org/10.1016/j.ccell.2020.03.011
doi: 10.1016/j.ccell.2020.03.011
Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8:30. https://doi.org/10.1186/s40478-020-00902-z
doi: 10.1186/s40478-020-00902-z
Lassaletta A, Zapotocky M, Mistry M et al (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35:2934–2941. https://doi.org/10.1200/JCO.2016.71.8726
doi: 10.1200/JCO.2016.71.8726
Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Bakry D, Laughlin S, Shlien A, Chan J, Ligon KL, Rutka JT, Dirks PB, Taylor MD, Greenberg M, Malkin D, Huang A, Bouffet E, Hawkins CE, Tabori U (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 33(9):1015–1022. https://doi.org/10.1200/JCO.2014.58.3922
doi: 10.1200/JCO.2014.58.3922
Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17(14):4790–4798. https://doi.org/10.1158/1078-0432.CCR-11-0034
doi: 10.1158/1078-0432.CCR-11-0034
Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, Cohen KJ, Eberhart CG (2011) BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res 17(11):3590–3599. https://doi.org/10.1158/1078-0432.CCR-10-3349
doi: 10.1158/1078-0432.CCR-10-3349
Buhl JL, Selt F, Hielscher T, Guiho R et al (2019) The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma. Clin Cancer Res 25(6):1851–1866. https://doi.org/10.1158/1078-0432.CCR-18-1965
doi: 10.1158/1078-0432.CCR-18-1965
Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF (2010) Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 119(5):641–649. https://doi.org/10.1007/s00401-009-0634-9
doi: 10.1007/s00401-009-0634-9
Jones DT, Witt O, Pfister SM (2018) BRAF V600E status alone is not sufficient as a prognostic biomarker in pediatric low-grade glioma. J Clin Oncol 36(1):96. https://doi.org/10.1200/JCO.2017.75.8987
doi: 10.1200/JCO.2017.75.8987
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. NeuroOncology 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106.O.D
doi: 10.1093/neuonc/noab106.O.D
Leonard JR, Perry A, Rubin JB, King AA, Chicoine MR, Gutmann DH (2006) The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 67(8):1509–1511. https://doi.org/10.1212/01.wnl.0000240076.31298.47
doi: 10.1212/01.wnl.0000240076.31298.47
Kollmann P, Mautner VF, Koeppen J et al (2020) MRI based volumetric measurements of vestibular schwannomas in patients with neurofibromatosis type 2: comparison of three different software tools. Sci Rep 10:11541. https://doi.org/10.1038/s41598-020-68489-y
doi: 10.1038/s41598-020-68489-y
Harris GJ, Plotkin SR, Maccollin M, Bhat S, Urban T, Lev MH, Slattery WH (2008) Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 62(6):1314–1319. https://doi.org/10.1227/01.neu.0000333303.79931.83
doi: 10.1227/01.neu.0000333303.79931.83
Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I, Ramaswamy V, Bartels U, Huang A, Laperriere N, Dirks P, Nathan PC, Greenberg M, Malkin D, Hawkins C, Bandopadhayay P, Kieran MW, Manley PE, Bouffet E, Tabori U (2016) Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer 122(8):1261–1269. https://doi.org/10.1002/cncr.29907
doi: 10.1002/cncr.29907
Nageswara Rao AA, Packer RJ (2014) Advances in the management of low-grade gliomas. Curr Oncol Rep 16(8):398. https://doi.org/10.1007/s11912-014-0398-9
doi: 10.1007/s11912-014-0398-9
Roder C, Breitkopf M, Bisdas S, da Silva Freitas R, Dimostheni A, Ebinger M, Wolff M, Tatagiba M, Schuhmann MU (2016) Beneficial impact of high-field intraoperative MRI on effectivity of pediatric low-grade glioma surgery. Neurosurg Focus. 40(3):13. https://doi.org/10.3171/2015.11.FOCUS15530
doi: 10.3171/2015.11.FOCUS15530
Lorenzen A, Groeschel S, Ernemann U, Wilke M, Schuhmann MU (2018) Role of presurgical functional MRI and diffusion MR tractography in pediatric low-grade brain tumor surgery: a single-center study. Childs Nerv Syst 34(11):2241–2248. https://doi.org/10.1007/s00381-018-3828-4
doi: 10.1007/s00381-018-3828-4
Carai A, De Benedictis A, Calloni T, Onorini N, Paternò G, Randi F, Colafati GS, Mastronuzzi A, Marras CE (2021) Intraoperative ultrasound-assisted extent of resection assessment in pediatric neurosurgical oncology. Front Oncol 11:660805. https://doi.org/10.3389/fonc.2021.660805
doi: 10.3389/fonc.2021.660805
Lawson AR, Tatevossian RG, Phipps KP, Picker SR, Michalski A, Sheer D, Jacques TS, Forshew T (2010) RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol 120(2):271–273. https://doi.org/10.1007/s00401-010-0693-y
doi: 10.1007/s00401-010-0693-y
Faulkner C, Ellis HP, Shaw A et al (2015) BRAF fusion analysis in pilocytic astrocytomas: KIAA1549-BRAF 15–9 fusions are more frequent in the midline than within the cerebellum. J Neuropathol Exp Neurol 74(9):867–872. https://doi.org/10.1097/NEN.0000000000000226
doi: 10.1097/NEN.0000000000000226
Mandonnet E, Pallud J, Fontaine D et al (2010) Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurg Rev 33(1):91–96. https://doi.org/10.1007/s10143-009-0229-x
doi: 10.1007/s10143-009-0229-x
Pallud J, Mandonnet E, Duffau H, Kujas M, Guillevin R, Galanaud D, Taillandier L, Capelle L (2006) Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas. Ann Neurol 60(3):380–383. https://doi.org/10.1002/ana.20946
doi: 10.1002/ana.20946